NCT02003313

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine in More Than 2 Years Old Children and Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,260 (actual)
• Sponsor: Beijing Minhai Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 2 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The purpose of this double-blind study is to evaluate the safety, reactogenicity and immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30 years-old Children and Adults. All subjects will receive 1 dose of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine.

Conditions

• Meningitis

Interventions

Type	Name	Description
BIOLOGICAL	Group T	0.5ml, Intramuscular
BIOLOGICAL	Group C	0.5ml, Intramuscular

Timeline

• Start date: 2013-11-01
• Primary completion: 2015-05-01
• Completion: 2015-07-01
• First posted: 2013-12-06
• Last updated: 2015-09-22

Locations

1 site across 1 country: China